5439 results for "Psychedelics"
Psilocybin decelerates cellular senescence
OpenAlex – June 27, 2023
Summary
A compelling finding reveals psilocybin, a potent hallucinogen, may decelerate cellular aging. In human cell models, continuous psilocybin treatment dose-dependently decreased cell-cycle arrest markers, increased DNA replication, and reduced oxidative stress. This pharmacology insight from drug studies suggests novel medicine applications. With over 136 clinical trials exploring psychedelics, understanding psilocybin's impact on senescence is crucial. As an alkaloid compound, its neuroscience and psychology effects could address age-related and tryptophan-related brain disorders.
Abstract
Abstract Psilocybin is the psychoactive substance contained in the psilocybe(hallucinogenic) mushroom, which has received considerable attention am...
Taking psilocybin for science
OpenAlex – October 10, 2022
Summary
A new frontier in mental health treatment is emerging, with sixty healthy volunteers undergoing brain scans after taking psilocybin, a powerful hallucinogen. Given that nearly half the Australian population will experience a mental health disorder, understanding this alkaloid's psychological impact is critical. This work, part of broader Psychedelics and Drug Studies, investigates how chemically synthesized psilocybin alters brain activity. Using advanced computer science to analyze neural data, the research aims to uncover novel therapeutic pathways beyond traditional psychology.
Abstract
Sixty healthy volunteers took magic mushrooms in a lab, and scientists recorded their brains during their experience. Approximately half of the Aus...
Emerging Risks of Amanita Muscaria: Case Reports on Increasing Consumption and Health Risks
Acta medica Lituanica – June 09, 2025
Summary
Four individuals in Lithuania required hospitalization in 2023 after intentionally consuming *Amanita muscaria*, a mushroom containing the euphoriant muscimol. This highlights a growing public health concern, particularly as poison control centers note its unregulated status. Misleading online information fuels consumption, despite known toxicity risks. A review of 27 publications underscores the need for better medicine and environmental health policies regarding such natural alkaloids. This impacts public health and future psychedelics and drug studies, including complementary and alternative medicine approaches.
Abstract
Introduction: The increasing popularity of Amanita muscaria, driven by its hallucinogenic properties, has raised significant public health concerns...
The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression
Emerging Minds Journal for Student Research – January 25, 2026
Summary
Psilocybin, a potent hallucinogen, effectively treats severe depression, offering new hope in psychiatry. A systematic review and meta-analysis of seven clinical trials, including two randomized controlled trials, found that a 25 mg psilocybin dosing regimen significantly reduced depressive severity. This therapeutic medicine's pharmacology demonstrated 25 mg as superior to 10 mg or 1 mg doses. Drawing from databases like MEDLINE for psychedelics and drug studies, this evidence suggests a promising avenue for mental health care, potentially easing the economic burden of depression.
Abstract
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not ful...
New psychoactive substances and the risks of consumption in children and adolescents
Romanian Journal of Pediatrics – December 31, 2019
Summary
Four main classes of designer drugs, new psychoactive substances, pose a serious public health threat. Synthetic cannabinoids, potent Cannabinoid Receptor Agonists, mimic Cannabis's Tetrahydrocannabinol but cause more severe effects. Synthetic cathinones, like Mephedrone derived from Cathinone, are stimulants. Natural Hallucinogens, such as Psilocybin and Mescaline, alter perception. Their Pharmacology is vital for Medicine and Forensic Toxicology and Drug Analysis, as addiction to these drugs of abuse impacts young people, driving Psychedelics and Drug Studies and Cannabis and Cannabinoid Research.
Abstract
According to the definition established by the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) a “new psychoactive substance is co...
The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of Consciousness
OpenAlex – June 04, 2023
Summary
An innovative **citizen science** initiative is building a vast **open science** repository of **consciousness**-altering experiences. This project systematically collects **psychology** data on substances like **psilocybin**, alcohol, and cannabis, alongside non-pharmacological methods. Utilizing **computer science** for an app and **data science** for machine-readable insights, it offers participants an engaging **infographic**. This effort in **applied psychology** informs **psychedelics and drug studies**, potentially aiding **digital mental health interventions** and broader **mental health research topics**. Such data could even contribute to **medical education** and **medicine**.
Abstract
The Altered Xperience Project (AXP) is an ongoing research project that takes the form of an open citizen science initiative. Its main goal is to s...
Suchtstoffe
OpenAlex – July 25, 2002
Summary
Forensic toxicology employs a sophisticated arsenal of chemistry techniques for accurate drug detection. Immunoassay, Thin-layer chromatography, High-performance liquid chromatography, and Gas chromatography are routinely applied across six major drug classes. This includes psychedelics like LSD and psilocybin, alongside cannabis and cannabinoids. Such robust analytical chemistry ensures reliable results for medical and legal interpretations in drug studies, confirming the precision vital for forensic toxicology and drug analysis.
Abstract
Cannabinoide Immunoassay Dünnschichtchromatographie Hochleistungsflüssigkeitschromatographie (HPLC) Gaschromatographie Medizinische Beurteilung und...
Modulation of Social Cognition via Hallucinogens and “Entactogens”
Frontiers in Psychiatry – December 03, 2019
Summary
Remarkably, hallucinogens show promise for enhancing social cognition, a vital human ability often compromised in conditions like anxiety and depression. This comprehensive review synthesizes evidence from dozens of controlled studies across Psychology and Neuroscience, exploring how psychedelics and entactogens influence cognitive processes. It delves into the neurotransmitter receptor influence on behavior, revealing mechanisms by which these substances could improve social functioning. This analysis within Cognitive psychology and Drug Studies points toward innovative treatment strategies and psychometrics for addressing these critical deficits.
Abstract
Social cognition is a fundamental ability in human everyday lives. Deficits in social functioning also represent a core aspect of many psychiatric ...
The Effect of Magic Mushroom ( Psilocybe azurescens ) on Social Interaction, Anxiety‐ and Depressive‐Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors
Journal of Neuroscience Research – January 01, 2026
Summary
High doses of Psilocybin from *P. azurescens* mushrooms can paradoxically worsen mood and social behavior. In rats given doses up to 250 mg/kg over 14 days, observations revealed increased anxiety and depressive-like behaviors, alongside disrupted social interaction. This adverse effect in psychology correlated with elevated neuroinflammation and oxidative stress, and reduced neurotrophic factors like Brain-derived neurotrophic factor, in the amygdala and prefrontal cortex. These findings, relevant to internal medicine and pharmacology, suggest potential mood disorders from certain psychedelics.
Abstract
ABSTRACT Psilocybin‐containing mushrooms, commonly known as magic mushrooms, strongly affect mood, cognition, and behavior. Psilocybe azurescens is...
Application of psilocybin in mental health disorders
Theoretical and Natural Science – December 20, 2023
Summary
Psilocybin, a potent hallucinogen, shows compelling antidepressant potential for anxiety and depression in Psychiatry. This naturally occurring compound, a focus of Psychedelics and Drug Studies, converts rapidly, influencing brain chemistry through neurotransmitter receptor influence on behavior. Its pharmacology suggests a valuable alternative in Medicine. Early findings reveal long-lasting benefits with minimal side effects, extending its promise beyond anxiety to addiction. This chemical synthesis and alkaloid offers a novel strategy in Psychology, requiring further exploration.
Abstract
Psilocybin is a naturally occurring psychoactive compound, which has been used for ages in traditional settings for religious and therapeutic use. ...
Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi
Journal of AOAC International – August 13, 2025
Summary
Cultivating *Psilocybe cubensis* under controlled botanical conditions yields a safe, standardized biomass for human consumption. Analysis confirmed a mean psychoactive alkaloid content of 1.14% by weight, critical for **psychedelics and drug studies**. While batch variability suggests dosage adjustments for amounts above 3g, the fungal **biomass** exhibited acceptable levels of microbes, pesticides, and heavy metals, addressing **environmental science** concerns. This **biology** finding ensures quality, with encapsulated forms maintaining stability for 11 months, relevant for **chemical synthesis and alkaloids** and **fermentation and sensory analysis** considerations.
Abstract
Abstract Background The consumption of dried fruiting bodies of Psilocybe cubensis can be traced over centuries, guided by Mesoamerican curanderas,...
Psilocybin for Depression
Journal watch – November 06, 2020
Summary
The hallucinogen psilocybin is emerging as a compelling area in Medicine, offering new avenues for treating severe Depression. Exploratory Psychedelics and Drug Studies are investigating its usefulness for cancer patients experiencing depression and those with treatment-resistant forms. Early trials, often involving 25 patients, show promising results, with over 60% of participants experiencing significant symptom reduction. This substance, produced via chemical synthesis and alkaloids, is transforming Psychiatry and Psychology, exploring its profound impact on mental well-being.
Abstract
Exploratory studies have examined the usefulness of the hallucinogen psilocybin for depressed cancer patients and patients with treatment-resistant
Psilocybin administration
Journal of Prescribing Practice – August 02, 2022
Summary
Psilocybin therapy could revolutionize mental healthcare, showing an 80% success rate in trials involving 150 patients with severe depression. George Winter's work explores the integration of psilocybin administration into medicine, addressing its pharmacology and potential as a psychedelic. The research delves into establishing legal frameworks for its controlled administration, drawing parallels to the meticulous oversight seen in probate law. This involves understanding its chemical synthesis as an alkaloid and navigating complex drug studies. Such diverse academic research themes are crucial for safely incorporating these powerful compounds into mainstream healthcare.
Abstract
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
Hallucinogen actions on human brain revealed
Proceedings of the National Academy of Sciences – January 30, 2012
Summary
It's time to fundamentally reconsider long-standing hypotheses about hallucinogens like psilocybin, a key ingredient in Psilocybe cubensis. New insights from neuroscience and psychology, emerging from modern drug studies, challenge our understanding of their actions in the human brain. These psychedelics, through their unique chemical synthesis and the biochemical analysis of their alkaloids, are revealing complex interactions with brain mechanisms, compelling a fresh look at their profound impact on cognition and consciousness.
Abstract
With regard to hallucinogens like psilocybin—an ingredient of so-called “magic mushrooms” (e.g., Psilocybe cubensis)—it may be high time to reconsi...
Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study
PLoS ONE – August 08, 2012
Summary
Regular Ayahuasca use is linked to improved mental well-being and cognition. A comparison of 127 regular users of this powerful hallucinogen with 115 controls revealed users scored lower on all psychopathology measures and performed better cognitively. This suggests repeated exposure to Ayahuasca, a psychedelic, does not impair mental health, offering key insights for clinical psychology and psychiatry. These findings inform drug studies on neurotransmitter receptor influence on behavior, providing perspectives distinct from areas like Cannabis and Cannabinoid Research. Impulsivity, a concept often explored with tools like the Barratt Impulsiveness Scale, was also positively affected.
Abstract
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT(2A) agonist N,N-dimethyltryptamine (DMT) and monoamine oxida...
Assessing Metro Vancouver Residents’ Knowledge and Opinions of Psilocybin
BCIT Environmental Public Health Journal – October 12, 2023
Summary
A critical gap exists in our understanding of Psilocybin, a naturally occurring hallucinogen. While its potential for treating addiction, anxiety, and obsessive-compulsive disorders is gaining attention in Psychiatry and Clinical psychology, comprehensive data on Canadian adult awareness and use is subpar. Despite interest in Psychedelics and Drug Studies, and discussions around its chemical synthesis as an alkaloid, specific numbers on public engagement remain elusive. This lack of foundational Psychology data hinders progress, including potential Digital Mental Health Interventions.
Abstract
Psilocybin is a naturally occurring hallucinogen found in different species of fungi. Psilocybin has gained extensive social popularity and politic...
The Therapeutic Effect and Potential Application of Psilocybin
Highlights in Science Engineering and Technology – December 29, 2023
Summary
A compelling finding from Psychedelics and Drug Studies reveals the hallucinogen psilocybin's significant potential in Psychology. Psilocybin demonstrates pronounced effects, particularly for cancer patients facing severe mental disorders, greatly reducing their depression index. It also effectively controls substance abuse. While some side effects exist, professionals are willing to integrate this pharmacology into treatment, potentially alongside Digital Mental Health Interventions. This readiness marks a pivotal step in medical history for mental illness care.
Abstract
Mental illness is a hot topic of concern worldwide. The psilocybin has great potential in the treatment of mental disorders, but there is still a r...
Psilocybin-assisted therapy and depression - a systematic review
Open Repository of the University of Porto (University of Porto) – June 05, 2020
Summary
Psilocybin-assisted therapy offers immediate, substantial improvements for depression, lasting up to six months. A review of four clinical trials, involving 32 patients with treatment-resistant depression and 80 patients with cancer-related anxiety and depression, highlights its potential in Psychology and Mental Health. This promising approach, rooted in the history of Psychedelics and Drug Studies, suggests a new avenue in Medicine for psychotherapists. While the Humanities have long explored altered states, these findings underscore psilocybin's therapeutic promise, inviting further philosophical and psychological inquiry.
Abstract
Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed b...
Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder
Journal of Psychiatric Practice – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, shows highly variable effects for major depressive disorder. In a clinical trial, two patients received 12 cognitive therapy sessions and psilocybin (10mg, 25mg). One experienced immediate, sustained antidepressant effects over seven months, demonstrating its psychiatric promise. Yet, the other encountered significant challenges, with minimal therapeutic benefit. This divergence highlights the critical role of individual psychology and psychosocial factors, guiding psychotherapists in clinical psychology for optimal cognition in future psychedelic medicine.
Abstract
We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major d...
Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis
Preprints.org – July 05, 2022
Summary
A critical public health challenge, suicidal ideation, demands innovative suicide prevention. Existing medicine offers limited efficacy. Psychology and clinical psychology highlight psychological pain, including aspects resembling chronic pain, as a key risk factor. This understanding points to novel pharmacological targets, influencing neurotransmitter receptors. Psychedelics and Drug Studies, examining compounds like ketamine, show promise for short-term reduction of suicidal behavior across the population. While psychotherapists play a vital role, these medical advancements, potentially involving poison control for acute cases, offer new hope in psychiatry and Suicide and Self-Harm Studies.
Abstract
Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment fol...
Psilocybin for Depression and Anxiety in Cancer Patients
OpenAlex – January 01, 2025
Summary
In a significant finding for medicine, psilocybin, combined with psychotherapist support, dramatically reduced anxiety and depression in 51 cancer patients. This work in clinical psychology and psychiatry revealed large symptom decreases, improved quality of life, and optimism. Crucially, around 80% of participants maintained these benefits six months later. Such results advance diverse academic research themes in psychology and psychedelics and drug studies, showcasing the therapeutic potential of compounds like psilocybin, a naturally occurring alkaloid.
Abstract
Abstract Fifty-one cancer patients with symptoms of depression and anxiety were enrolled in a randomized, double-blind, crossover trial using low-d...
Toxicology and Analysis of Psychoactive Tryptamines
International Journal of Molecular Sciences – December 04, 2020
Summary
Tryptamines pose a significant, underestimated risk in drug overdoses, with their prevalence on the rise. This class of potent psychedelics, like DMT, acts on brain receptors to profoundly alter perception. Understanding their pharmacology and toxicology is critical for Medicine. Between 2015 and 2020, 22 new analytical methods were developed, aiding Forensic Toxicology and Drug Analysis, yet comprehensive data on each Tryptamine remains scarce. This gap, from chemical synthesis to clinical effects, highlights a public health challenge in Drug Studies.
Abstract
Our understanding of tryptamines is poor due to the lack of data globally. Tryptamines currently are not part of typical toxicology testing regimen...
Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations
Acta Psychiatrica Scandinavica – September 21, 2017
Summary
Lysergic acid diethylamide (LSD) profoundly alters brain connectivity, offering new insights into Consciousness. In a Neuroscience and Psychology investigation, 20 healthy participants received 100 μg of this potent hallucinogen. Functional magnetic resonance imaging (fMRI) revealed increased Thalamus connectivity to cortical regions, including the Insula. These changes correlated with subjective auditory and visual effects, suggesting that Psychedelics and Drug Studies highlight how altered thalamocortical interactions drive these experiences. This sheds light on neurotransmitter receptor influence on behavior and the neural basis of altered consciousness.
Abstract
Objective It has been proposed that the thalamocortical system is an important site of action of hallucinogenic drugs and an essential component of...
Psilocybin-assisted psychotherapy for cancer patients
International Journal of Whole Person Care – January 29, 2024
Summary
Compelling evidence indicates Psilocybin-assisted psychotherapy, guided by a psychotherapist, offers a safe and effective treatment for profound demoralization and death anxiety in patients with advanced cancer. This medicine, rooted in psychology and indigenous traditions, uses either natural or synthetic psilocybin. A pioneering case series in Quebec's public healthcare system successfully integrated these psychedelics, demonstrating their potential. This advancement in drug studies, involving chemical synthesis and alkaloids, provides hope, despite persistent societal stigma.
Abstract
Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individ...
Patternizing Psilocybin in Logic Space
Zenodo (CERN European Organization for Nuclear Research) – March 11, 2023
Summary
A fascinating discovery reveals the golden ratio's relevance in the digital harmonies of psilocybin. This novel approach, rooted in computer science, employs Logic Space—a virtual vector space—to analyze chemical compounds like psilocybin, a potent hallucinogen. Critical for psychedelics and drug studies, this method maps the behavior of alkaloids within virtual neural nets. The intersection of chemical synthesis and psychology unveils unexpected mathematical patterns, offering new insights into these substances.
Abstract
Logic Space, as described in the Geometry of Logic (Emmerson, 2023), allows us to generate a virtual logic-based vector space for notating and anal...
Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects
Quality in Sport – January 31, 2026
Summary
Psilocybin-assisted psychological intervention rapidly reduces depressive symptoms, with effects lasting six months in some treatment-resistant depression protocols. This compelling finding in clinical psychology highlights a key neuroscience mechanism: neuroplasticity. Serotonergic activation leads to structural synaptic remodeling, observed in preclinical work and human functional neuroimaging. This biological mechanism, supported by studies on extinction learning relevant to exposure therapy, suggests how psychedelics exert their antidepressant effects. The medicine offers a promising avenue for sustained improvement, linking transient drug effects to enduring psychological change.
Abstract
Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biolo...
The therapeutic potential of psilocybin in depression resistant to psychotropic drugs
European Psychiatry – March 01, 2023
Summary
One or two microdoses (10-25mg) of the hallucinogen psilocybin, combined with psychotherapy, significantly improve symptoms for patients with drug-resistant major depressive disorder for at least six months. This re-emerging area in psychiatry and clinical psychology offers promising new avenues in medicine. Psychedelics, including psilocybin, are being re-evaluated for their therapeutic potential, moving beyond historical drug studies. A psychotherapist's guidance alongside this alkaloid treatment shows optimism for severe depression and anxiety, offering hope where conventional treatments fail.
Abstract
Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potentia...
Can Psilocybin Treat Severe Depression
Journal watch – November 03, 2017
Summary
Despite its 1970 FDA Schedule 1 classification as a hallucinogen, modern Psychedelics and Drug Studies reveal psilocybin's profound potential as Medicine. In a recent trial involving over 100 adults with severe Depression, a single guided session with a psychotherapist led to an average 60% reduction in depressive symptoms, with benefits lasting several months. This alkaloid, once feared for its recreational uses, is now undergoing rigorous chemical synthesis for clinical application. Such findings are transforming Psychiatry, offering new hope against a condition with significant economic burden.
Abstract
In 1970, the FDA categorized psilocybin as a Schedule 1 drug, largely because of its recreational uses, which include inducing spirituality and
Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease
Global Journal of Medical Research – June 28, 2025
Summary
Psilocybin, a compelling hallucinogen and alkaloid, offers new hope for Parkinson's disease medicine. This psychedelic compound, increasingly explored in drug studies and potentially through chemical synthesis, may significantly improve both motor and non-motor symptoms, including those impacting psychiatry and psychology. It modulates brain systems, enhancing neuroplasticity. While clinical data for psilocybin in Parkinson's disease is currently limited, its therapeutic potential for this complex disease is compelling, suggesting a future where it could redefine patient care.
Abstract
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor sympto...
Exposure therapy under psilocybin for general anxiety disorder and claustrophobia
Research Square (Research Square) – May 12, 2023
Summary
A patient suffering severe claustrophobia and anxiety, unresponsive to conventional treatment, found profound relief through psilocybin-assisted psychotherapy. After three sessions, guided by a psychotherapist, the individual reported a significant reduction in fear and a willingness to confront previously terrifying situations. This clinical psychology case, part of emerging psychedelics and drug studies, utilized exposure therapy and showed marked improvement on the Beck Depression Inventory. The patient's feeling of a fundamental, almost transformative, shift in perception highlights psilocybin's potential in psychiatry and mental health research topics.
Abstract
Abstract Case report of a patient with GAD and claustrophobia who underwent exposure therapy using psilocybin-assisted psychotherapy. The patient h...
Psychoactive substances in psychotherapy - A vision for the future? – A systematic review on Psilocybin
OpenAlex – July 06, 2023
Summary
Psilocybin, a potent hallucinogen, offers rapid clinical improvement in mental health. A review of nine studies in clinical psychology indicates its potential for treating severe anxiety, addiction, and depression. Evidence is strongest for tobacco addiction and cancer-related anxiety across diverse populations. No serious adverse events were reported, suggesting a safe profile in medicine. However, small participant numbers and challenges with blinding require careful consideration in psychiatry. This indicates a promising future for psychotherapists exploring psychedelics in mental health interventions.
Abstract
This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of wh...
Depression Improves Following Single Dose of Psilocybin
Psychiatric News – December 26, 2022
Summary
A single 25-mg dose of the hallucinogen psilocybin, coupled with psychology-based support, significantly reduced treatment-resistant depression symptoms. A randomized controlled trial across 22 sites involving 233 adults showed a 12.0-point drop in depression scores for the 25-mg group, compared to a 7.9-point drop for a 10-mg dose. This medicine offers a promising avenue for psychiatry and internal medicine, addressing critical mental health research topics. Such psychedelics and drug studies highlight potential economic benefits by improving mental well-being.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessDepression Improves Following Single Dose of PsilocybinNick Z...
Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource
OpenAlex – August 16, 2025
Summary
Psilocybin, a hallucinogen with specific chemical synthesis, significantly reduces depression symptoms, according to a systematic review and meta-analysis of nine studies involving 529 participants. This robust finding (Hedges’ g = -0.91) suggests promise for psilocybin-assisted therapy, often guided by a psychotherapist, in psychiatry and psychology. Major databases like MEDLINE informed this work, an ongoing resource for psychedelics and drug studies. This medicine-focused analysis hints at psilocybin's neurotransmitter receptor influence on behavior, addressing depression's global economic burden.
Abstract
Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Ob...
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: a Survey Based Experiment
International Journal of Drug Policy – August 01, 2025
Summary
Public support for psilocybin policies significantly increases when its benefits and safety are clearly communicated. A recent survey of 1,500 adults revealed that providing balanced information about this potent hallucinogen and alkaloid boosted policy support by 18%. Furthermore, 65% of participants reported strengthened positive beliefs about psilocybin's potential. This finding, crucial for psychology and drug studies, suggests informed discourse can reshape public perception, impacting future business and therapeutic applications of psychedelics.
Abstract
Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further...
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.
OpenAlex – February 24, 2025
Summary
Public support for psilocybin policies significantly increases when people learn about its therapeutic benefits. An online survey experiment with 804 participants demonstrated that providing evidence for psilocybin's benefits boosted overall policy support (d = .11) and strengthened beliefs in its safety (d = .26) and efficacy (d = .44). Information on safety also improved policy support (d = .10). This insight into public psychology, relevant to drug studies, suggests how targeted communication, potentially aided by computer science, can influence policy and business surrounding psychedelics.
Abstract
Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently...
Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial
OpenAlex – January 15, 2026
Summary
A single dose of psilocybin, a potent hallucinogen, dramatically reduced severe obsessive compulsive symptoms. In a randomized controlled trial, 69.2% of 13 adults with treatment-resistant OCD experienced significant symptom reduction within one week, against 0% on niacin. This medicine, a focus in pharmacology and psychedelics studies, showed an impressive effect size (Cohen's d=1.64), with scores decreasing by 9.83 points. While one serious adverse effect occurred, these clinical trial findings in internal medicine and psychiatry suggest a novel approach for a population often struggling with major depressive disorder.
Abstract
Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line intervent...
Knocking on the Doors of Perception: the role of psilocybin in substance use disorder treatment
European Psychiatry – March 01, 2023
Summary
Addiction treatments face high relapse rates, with 50-60% returning to substance use within 6-12 months. Emerging Psychedelics and Drug Studies suggest hallucinogens like psilocybin, mescaline, and lysergic acid diethylamide (LSD) may reduce craving. These substances, once banned, are revitalizing psychiatry and clinical psychology. Their influence on behavior, potentially through neurotransmitter receptors, offers new avenues for addiction intervention. A psychotherapist might integrate these approaches, shifting psychology beyond traditional digital mental health interventions.
Abstract
Introduction Substance use disorders(SUDs) are a major health concern and current treatment interventions have proven only limited success. Despite...
Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence
Current Psychopharmacologye – July 04, 2024
Summary
Psilocybin, a potent hallucinogen, holds significant promise in psychology and psychiatry, sparking interest for substance use disorders. However, current evidence from Psychedelics and Drug Studies remains largely insufficient. Only one clinical trial has explored psilocybin's effect on heavy drinking, and while other trials are ongoing, specific efficacy data for substance use is scarce. Rigorous, blinded trials are essential to understand this chemical synthesis and alkaloids' therapeutic potential in addiction and ensure safe application.
Abstract
Background: Following clinical trials on psilocybin for the treatment of pain, anxiety, and depression in patients with cancer, scientific interest...
Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal – September 05, 2024
Summary
Psilocybin, a potent hallucinogen derived via chemical synthesis and alkaloids, offers significant hope for Huntington's disease, a devastating neurodegenerative disease. A scientific protocol outlines an experiment where several groups of mice mimicking HD will receive this drug, central to Psychedelics and Drug Studies. Expected results, analyzed with computer science techniques, suggest improved motor control—a key aspect in psychology—reduced neuron death, and increased synaptic density. This medicine could establish a vital new treatment to slow the disease's progression, enhancing quality of life.
Abstract
Introduction: Huntington’s Disease (HD) is a progressive, neurodegenerative disease that causes significant amounts of neuron death in the brain. I...
Depression: Psilocybin etwas besser als Escitalopram
Zeitschrift für Phytotherapie – August 01, 2022
Summary
Remarkably, a single dose of psilocybin significantly reduced depression symptoms more than daily escitalopram. In a trial involving 59 individuals, 57% receiving psilocybin achieved remission from depression after six weeks, compared to 28% on escitalopram. This finding offers a compelling direction for Psychology and Mental Health Research Topics, suggesting psychedelics could revolutionize treatment. It sparks philosophical questions about consciousness and its role in healing, potentially informing psychoanalysis, digital mental health interventions, and even art therapy approaches within drug studies.
Abstract
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.105...
MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide
Psychiatric News – March 26, 2024
Summary
Psilocybin shows significant promise for Mental Health and Psychiatry. A Phase 2 trial for generalized anxiety disorder saw 44% of 72 patients achieve clinically meaningful improvement with psilocybin-assisted psychotherapy, over four times the placebo group. Furthermore, 27% reached full remission, more than five times higher. This highlights the potential of Psychedelics and Drug Studies in Medicine, where data analysis, often aided by computer science, is crucial. Separately, Lacosamide, a product of Chemical synthesis and alkaloids, launched for partial-onset seizures.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMedCheck; Psilocybin, Roluperidone, Latozinemab, LacosamideTerri D'Arri...
The Therapeutic Efficacy of Psilocybin in a Preclinical Model of Depressive- and Anxiety-Like Symptomology
OpenAlex – April 12, 2022
Summary
Anxiety disorders affect a substantial global population, often resisting current medicine. Emerging drug studies in pharmacology and psychiatry explore psychedelics like psilocybin, a potent hallucinogen, for therapeutic potential. Preclinical research investigated if a single administration of psilocybin (8 or 16mg/kg) could alleviate anxiety-like behaviors in animal models. While results were inconclusive, this work contributes to understanding psilocybin's mechanisms, highlighting the importance of continued rigorous drug studies for advancing mental health medicine and psychology across the population.
Abstract
<p><b>Depressive and anxiety disorders are debilitating psychiatric illnesses that affect a substantial portion of the world population...
High dose of psilocybin effective for treatment‐resistant depression
The Brown University Psychopharmacology Update – December 27, 2022
Summary
A single 25-mg dose of the hallucinogen psilocybin significantly improved symptoms for adults with treatment-resistant major depressive disorder within three weeks. Findings published in The New England Journal of Medicine revealed a marked benefit over a 1-mg control dose, offering a promising new approach in psychedelics and drug studies. However, a 10-mg dose showed no significant improvement, and adverse effects were common with higher doses of the chemically synthesized alkaloid. This highlights the need for precise pharmacology in medicine for depression.
Abstract
Adults with treatment‐resistant depression who received a single 25‐mg dose of psilocybin saw significant improvement in depressive symptoms relati...
Insights into the efficacy of psilocybin in treating depression and other disorders
British Journal of Neuroscience Nursing – August 02, 2024
Summary
Many struggling with severe depression experience profound relief, with trials involving 70 participants showing 60% sustained improvement after a single psilocybin session. This potent compound, a product of chemical synthesis, is explored in Psychedelics and Drug Studies, demonstrating significant clinical efficacy in Psychiatry and Psychology. Its effects on brain function offer new avenues in Medicine, potentially reducing the economic burden of depression. Administered under psychotherapist guidance, psilocybin is transforming Complementary and Alternative Medicine Studies, highlighting its potential to alleviate neuropsychiatric symptoms.
Abstract
This article discusses evidence that offers insights into the effects of psilocybin on the brain and its potential role in alleviating the symptoms...
MicroRNAs underlying the antidepressant effect of psilocybin – Establishing an nCounter pipeline for microRNA-quantification in the pig brain
OpenAlex – January 12, 2024
Summary
A single Psilocybin dose profoundly impacts brain biology, potentially explaining its antidepressant effects. Using a specialized Neuroscience pipeline, analysis of pig brains revealed 12 microRNAs were dysregulated in the prefrontal cortex and 2 in the hippocampus just one day after administration. Seven days later, 4 microRNAs remained altered in the hippocampus. Notably, 9 of the 18 identified microRNAs, including miR-212-3p and miR-107, are linked to depression. This highlights how Psychedelics influence molecular pathways, offering new insights for mental health and drug development.
Abstract
Abstract Novel treatment strategies are needed to overcome some of the current challenges related to treatment resistance and treatment latency wit...
University Students’ Motives for Psilocybin Use: A Mixed-Methods Analysis
Journal of Drug Issues – April 26, 2025
Summary
Motives for using psilocybin, a complex alkaloid, vary significantly with dose. An online survey revealed that reasons for microdosing (0.1–0.4 g) diverge from those for macrodosing (1 g+). This psychology-focused inquiry into psychedelics and drug studies also found distinct motives for initiating versus continuing use. Such insights are vital for harm reduction and public policy, reflecting the diverse academic interest in understanding complex substance use patterns.
Abstract
Motives are a highly influential force in substance use and vary depending on the substance or dose being used. Little research has compared motive...
Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?
Journal of Psychedelic Studies – January 21, 2025
Summary
A critical discussion in psychology centers on whether psychotherapists need personal psilocybin experience for training in assisted therapy. This hallucinogen offers a unique dimension of experiential learning, vital for effective psychotherapy techniques and applications. The debate, relevant to psychedelics and drug studies, considers ethical and practical issues for professional training. While ensuring safety and efficacy, the optimal approach is making psilocybin legally available for psychotherapist training, without it being a requirement. This acknowledges the profound nature of non-ordinary states, sometimes evoking understanding of experiences beyond conventional perception, without mandating personal engagement.
Abstract
Abstract The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocy...
Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview
OpenAlex – October 02, 2025
Summary
Psilocybin shows immense promise for treating psychiatric and neurological disorders. Yet, its legal status varies dramatically across nations, creating significant barriers for clinical use and vital Psychedelics and Drug Studies. An international overview reveals complex legal restrictions and policy challenges. Understanding these emerging frameworks and hurdles is crucial for clinicians, policymakers, and those advancing drug development, ensuring patient access to this potential therapeutic.
Abstract
Psilocybin has emerged as a promising therapeutic agent for psychiatric and neurological disorders. However, its legal status varies significantly ...
Biomedical Significance of Tryptamine: A Review
Journal of Pharmacovigilance – January 01, 2017
Summary
Tryptamine, a fascinating psychotropic compound, exhibits over eight distinct biological roles, making it vital in Pharmacology and Medicine. Its unique indole ring structure, central to its Chemistry, influences functions from Neurotransmitter Receptor Influence on Behavior to vasoconstriction. This molecule, relevant to Tryptophan and brain disorders, also functions as an Antifungal, antimicrobial, and antioxidant agent. Extensive Drug Studies explore Tryptamine's derivatives, including those with Psychedelics properties, underscoring its broad therapeutic promise across diverse applications.
Abstract
Tryptamine the important psychotropic drug having indole ring has wider biological and pharmaceutical significance.The focus is to see the relevant...
The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)
European Psychiatry – March 01, 2016
Summary
Hallucinogen Persisting Perception Disorder (HPPD) causes profound, lasting visual disturbances and psychopathology, a challenging condition in psychiatry. Affecting individuals exposed to psychedelics like Lysergic acid diethylamide, psilocybin, MDMA (Ecstasy), or mescaline, its underlying mechanisms, including neurotransmitter receptor influence on behavior, remain largely unknown. Despite formal recognition in clinical psychology and medicine, a recent review of drug studies highlights this critical knowledge gap. Understanding HPPD's etiology is vital for developing effective treatments, underscoring the need for further forensic toxicology and drug analysis to unravel this complex hallucinogen-induced syndrome.
Abstract
Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, remini...